Madrigal's Rezdiffra sales top forecasts as Gilead announces job cuts
read at Endpoints ↗EarningsNeutral
Madrigal Pharmaceuticals reported first‑quarter sales of its MASH drug Rezdiffra at $311 million, roughly $10 million above analyst expectations, according to TD Cowen.
The outperformance highlights continued demand for the therapy and supports Madrigal’s growth outlook for the year.
In separate news, Gilead Sciences disclosed a reduction in its workforce, though details on the size of the cuts were not provided.
Investment firm Banyan also announced its market debut, adding another player to the biotech financing landscape.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Madrigal's Rezdiffra beats estimates; Gilead cuts jobs; Banyan debuts”
read at Endpoints ↗80 words · retrieved May 6
comments(0)
5-min edit window · permanent after that